ArticleClinical cancer research : an official journal of the American Association for Cancer Research2022

Improved Efficacy of Tafasitamab plus Lenalidomide versus Systemic Therapies for Relapsed/Refractory DLBCL: RE-MIND2, an Observational Retrospective Matched Cohort Study.

Grzegorz S Nowakowski et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.